Differently from the previously mentioned studies, GeparX (NCT02682693), a recently terminated phase 2 trial that enrolled 780 BCa patients, evaluated whether the addition of denosumab to anthracyclin/taxan-containing neoadjuvant chemotherapy increased pCR rate and improved outcomes regarding RANK tumor expression. The gene discussed is TNFRSF11A; the disease is neoplasm.